Soleno Therapeutics Inc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Soleno Therapeutics Inc's ROA in the first quarter of 2026?
Soleno Therapeutics Inc achieved a return on average assets (ROA) of 18.27 % in its first quarter of 2026, this is above SLNO's average return on assets of -63.64%.
Soleno Therapeutics Inc assets over the 12 months ending in its first quarter of 2026 are valued at $526 million

Despite the company's net income deteriorating, Soleno Therapeutics Inc was able to improve its ROA compared to the fourth quarter of 2025.

However, within the Healthcare sector 54 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 265, from total ROA ranking in the fourth quarter of 2025 at 1449.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	91.68 %	70.81 %	102.45 %	8.51 %	87.44 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	96	21	-78	-181	-198
Return On Assets (TTM)	18.27 %	4.61 %	-19.89 %	-56.81 %	-63.49 %
SLNO's Total Ranking	# 265	# 1449	# 3544	# 4144	# 4301
Total Assets (TTM) in million	608	564	598	332	317
Seq. Total Assets Change	7.9 %	-5.79 %	80.39 %	4.53 %	-3.84 %
Seq. Net Income Change	-27.63 %	66.68 %	-	-	-

SLNO's 5 Years Annual ROA >> Back to SLNO Management Effectiveness >> Compare SLNO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 11
Sector	# 55
Overall	# 261

Return On Assets Statistics
High	Average	Low
60.71 %	-63.64 %	-168.88 %
(Sep 30 2015)		(Jun 30 2016)

News about Soleno Therapeutics Inc Return on Assets ROA

Hope on the Horizon FDA Extends Review for Diazoxide Choline in Prader-Willi Syndrome

Hope on the Horizon: FDA Extends Review for Diazoxide Choline in Prader-Willi Syndrome In a noteworthy development for patients and families facing Prader-Willi Syndrome (PWS), Soleno Therapeutics has announced an extension of the review period for its investigational drug, Diazoxide Choline Extended-Release Tablets (DCCR), by the U.S. Food and Drug Administration (FDA). Originally set to culminate in a decision this December, the new target action date is now March 27, 2025; a generous three-month extension that reflects the complexity and significance of this promising therapeutic avenue.PWS is a rare genetic disorder that affects approximately 1 in 15,000 newborns, leading to a myriad of challenges including hypotonia, developmental delays, and a life-altering hyperphagia that contributes to obesity and related comorbidities. The need for effective treatment options has long been a pressing concern in the clinical community and among affected families. DCCR has emerged as a beacon of hope, aiming to address some of the core symptoms of PWS, particularly hyperphagia the insatiable hunger that often leads to life-threatening obesity. By modulating the hypothalamus and influencing metabolic pathways, DCCR may offer a lifestyle-altering intervention that could significantly improve the quality of life for patients grappling with this disorder. During the FDA s review process, a rigorous evaluation of the data supporting DCCR s safety and efficacy is underway. Potential efficacy signals observed in clinical trials have garnered attention and ignited optimism within the PWS community. However, with such a rare disorder, the path to regulatory approval is fraught with complexities. The new extension allows for additional thorough analysis of existing data, an opportunity for the FDA to ensure that any decision made is based on robust and comprehensive evidence.

Financial Statements
Soleno Therapeutics Inc's Assets	$ 608 million	SLNO's Balance sheet
Soleno Therapeutics Inc's Income	$ 31 million	Quarterly SLNO's Income Statement
SLNO's Income by Division		See SLNO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	131.59 %	82.68 %	585.32 %	-25.84 %	-45.17 %
Total Assets in million	764	330	181	26	36
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	20	-176	-39	-24	-31
Annual Return On Assets	2.68 %	-53.27 %	-21.58 %	-91.28 %	-86.94 %

SLNO's 5 Years Annual ROA >> Back to SLNO Management Effectiveness >> Compare SLNO ROA to its Competitors

Comment on SLNO's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 2.68 % compared to prior year, due to annual net income growth of % to $20.48 million, while value of Soleno Therapeutics Inc's overall assets grew just by 131.59 % to $764.45 million, compared to $764.45 a year before.

More Return On Assets Ratios
SLNO's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SLNO's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SLNO's Competitors
Subscribers only: Roa for Soleno Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for SLNO's Customers

You may also want to know
SLNO's Roi	SLNO's Inventory Turnover Ratio	SLNO's Growth Rates	SLNO's Dividend Comparisons
	SLNO's Profitability Ratios	SLNO's Asset Turnover Ratio	SLNO's Dividend Growth
SLNO's Roe	SLNO's Valuation Ratios	SLNO's Financial Strength Ratios	SLNO's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector	ROA
Oramed Pharmaceuticals Inc	49.88 %
Aurinia Pharmaceuticals Inc	47.61 %
Zevra Therapeutics Inc	45.60 %
Earth Science Tech Inc	44.55 %
Tg Therapeutics Inc	42.77 %
Lensar Inc	42.26 %
Elite Pharmaceuticals Inc	38.74 %
Dariohealth Corp	37.08 %
Omeros Corporation	34.53 %
Idexx Laboratories Inc	32.56 %
Innoviva Inc	32.36 %
Agenus Inc	30.03 %
Abeona Therapeutics Inc	29.55 %
Escalon Medical Corp	29.20 %
Protagenic Therapeutics Inc new	27.96 %
Adma Biologics Inc	27.37 %
Rafael Holdings Inc	26.85 %
Acadia Pharmaceuticals Inc	26.24 %
Ironwood Pharmaceuticals inc	26.02 %
Theravance Biopharma inc	25.46 %
Spero Therapeutics Inc	24.95 %
Medpace Holdings Inc	24.79 %
Mettler toledo International Inc	24.47 %
Qhslab Inc	23.09 %
Eli Lilly And Company	22.73 %
Incyte Corporation	21.65 %
Iradimed Corporation	21.25 %
Catalyst Pharmaceuticals Inc	20.71 %
Engene Therapeutics Inc	20.52 %
Vaxart Inc	20.07 %

Date modified: 2026-09-12T06:14:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.